Core Viewpoint - Conmed (CNMD) reported a revenue of $321.26 million for the quarter ended March 2025, marking a year-over-year increase of 2.9% and exceeding the Zacks Consensus Estimate by 2.42% [1] Financial Performance - Earnings per share (EPS) for the quarter was $0.95, compared to $0.79 a year ago, resulting in an EPS surprise of 17.28% over the consensus estimate of $0.81 [1] - The stock has returned -13.9% over the past month, contrasting with the Zacks S&P 500 composite's -0.2% change, and currently holds a Zacks Rank 3 (Hold) [3] Revenue Breakdown - Domestic revenue reached $183.80 million, surpassing the two-analyst average estimate of $175.66 million, with a year-over-year change of +4.2% [4] - International revenue was $137.50 million, slightly below the average estimate of $138.31 million, reflecting a year-over-year change of +1.2% [4] - Net sales in Orthopedic Surgery totaled $138.30 million, exceeding the average estimate of $125.60 million, with a year-over-year increase of +2.5% [4] - Net sales in General Surgery were $183 million, slightly above the average estimate of $182.04 million, showing a year-over-year change of +3.2% [4] - Net sales of Single-use Products amounted to $276.30 million, surpassing the average estimate of $268.71 million, with a year-over-year change of +4.4% [4] - Net sales of Capital Products were $45 million, slightly below the average estimate of $45.25 million, indicating a year-over-year decline of -5.5% [4]

CONMED (CNMD) Q1 2025 Earnings Call April 30, 2025 04:30 PM ET Speaker0 Good day and thank you for standing by. Welcome to ConMed's First Quarter Fiscal twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your questio ...

NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Corporation Announces First Quarter 2025 Financial Results Largo, Florida, April 30, 2025 – CONMED Corporation (NYSE: CNMD) today announced financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights "We had a good start to 2025, which positions us well to achieve our full-year guidance," commented Patrick J. Beyer, CONMED's President and Chief Executive O ...

Investor Presentation Q1 2025 Earnings Pat J. Beyer President and Chief Executive Officer Todd W. Garner Executive Vice President and Chief Financial Officer April 30, 2025 Forward-Looking Information This presentation may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward- looking statements herein or in previous disclosures. ...

CONMED CORPORATION (Exact name of registrant as specified in its charter) | Delaware | 16-0977505 | | --- | --- | | (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | | 11311 Concept Boulevard | | | Largo, Florida | 33773 | | (Address of principal executive offices) | (Zip Code) | | (727) 392-6464 | | United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange ...

CONMED Corporation (CNMD) delivered fourth-quarter 2024 adjusted earnings per share (EPS) of $1.34, which beat the Zacks Consensus Estimate of $1.20 by 11.7%. The bottom line improved 26.4% from the year-ago level.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.GAAP EPS for the quarter was $1.08 compared with $1.50 in the year-ago period.CNMD’s Revenues in DetailCONMED’s revenues totaled $345.9 million, up 5.8% year over year. The top line beat the Zacks Consensus Estimate by 1.4%. At ...

Financial Data and Key Metrics Changes - Total sales for Q4 2024 were $345.9 million, a year-over-year increase of 5.8% as reported and 6% in constant currency [8] - GAAP net income for Q4 was $33.8 million, compared to $33.1 million in the prior year, while adjusted net income increased 26.2% year-over-year to $41.8 million [9][12] - For the full year, sales reached $1.307 billion, representing a 5% year-over-year growth as reported and 5.3% in constant currency [10] Business Line Data and Key Metrics Changes - Orthopedic business sales increased 2.4% in Q4 and 2.5% for the full year on a constant currency basis [10][21] - General Surgery business saw constant currency growth of 8.7% in Q4 and 7.5% for the full year [10][22] - AirSeal achieved strong double-digit growth, with record capital and disposable sales despite market dynamics [11] Market Data and Key Metrics Changes - U.S. sales increased 6.8% in Q4, while international sales grew 5.0% [19] - Total worldwide Orthopedic sales grew 2.4% in Q4, with U.S. Orthopedic sales growing 5.2% and international sales increasing 0.6% [20] - Total worldwide General Surgery sales increased 8.7% in Q4, with U.S. sales growing 7.4% and international sales increasing 12.0% [20] Company Strategy and Development Direction - The company is focused on resolving supply challenges in the Orthopedic business and maximizing growth drivers like AirSeal, Buffalo Filter, BioBrace, and Foot & Ankle portfolio [13][16] - A consulting firm has been engaged to expedite operational improvements and strengthen the Orthopedic business [14] - The company aims to enhance its portfolio's durability, growth, and profitability over the next decade [16][84] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth potential of AirSeal, driven by strong demand for improved patient outcomes [15] - The company is cautious in its 2025 guidance, projecting revenue growth of 4% to 6% in constant currency, reflecting current operational challenges [38][39] - Management acknowledged the impact of currency headwinds and ongoing operational improvements on profitability [70][92] Other Important Information - Adjusted gross margin for Q4 was 57.6%, a 120 basis point improvement year-over-year [23] - The company reported a cash balance of $24.5 million at year-end, down from $38.5 million [31] - Capital expenditures for the full year were $13.1 million, compared to $19.0 million in 2023 [34] Q&A Session Summary Question: What accounts for the delta in growth rates? - Management attributed the delta to lingering supply chain challenges that have affected performance [61] Question: What is the outlook for AirSeal growth? - Management expects AirSeal to continue growing at double-digit rates due to strong clinical demand [64] Question: What factors contribute to the conservatism in guidance? - The conservatism is due to market conditions, timing of new products, and ongoing supply chain issues [66][70] Question: What is the strategy for capital allocation and M&A? - The company plans to focus on paying down debt and improving leverage, while remaining open to compelling acquisition opportunities [104] Question: How is the company addressing the impact of tariffs? - Management indicated that passing on tariff costs to hospitals may be challenging due to existing contracts [111][112]

Conmed (CNMD) came out with quarterly earnings of $1.34 per share, beating the Zacks Consensus Estimate of $1.20 per share. This compares to earnings of $1.06 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 11.67%. A quarter ago, it was expected that this medical technology company would post earnings of $0.99 per share when it actually produced earnings of $1.05, delivering a surprise of 6.06%.Over the last four quarters, the ...

CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com CONMED Corporation Announces Fourth Quarter and Full-Year 2024 Financial Results NEWS RELEASE Largo, Fla. - February 5, 2025 – CONMED Corporation (NYSE: CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2024. Fourth Quarter 2024 Highlights Full-Year 2024 Highlights "2024 was a year of solid sales and earnings growth but was also challenging as we navigated persi ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use a variety of methods, inc ...